Hand rejuvenation injections are minimally invasive procedures designed to restore volume and improve skin quality of the dorsal hand using dermal fillers and biorevitalization injectables, selected according to the severity of subcutaneous atrophy and skin laxity as assessed by the Merz Hand Grading Scale.
Injectable hand rejuvenation is a non-surgical approach to correcting volume loss, skin laxity, and surface deterioration of the dorsal hand using biorevitalization injectables and volumising fillers. Treatments are selected according to severity, graded with the validated Merz Hand Grading Scale (MHGS), and address both dermal quality and subcutaneous atrophy.
KEY TAKEAWAYS
- The dorsal hand has a dermis of 0.2–0.9 mm — among the thinnest on the body — with direct implications for injection plane and product choice.
- Severity is graded with the Merz Hand Grading Scale (MHGS, 0–4). Treatment selection follows severity: biorevitalization for MHGS 0–1, combination for grade 2, volumisation first for grades 3–4.
- For skin quality, Ejal40, Sunekos 1200 and Profhilo H+L address hydration, ECM stimulation and bioremodelling respectively — each through distinct mechanisms.
- Radiesse (+) 1.5ml (CaHA) provides immediate volume and progressive collagen induction. Clinical RCT data (n=114) demonstrates 75% of patients achieving ≥1-grade MHGS improvement at 3 months.
- Careful injection technique, low-pressure delivery and anatomical awareness of dorsal venous anatomy are primary safety considerations.
- For patients already attending for facial treatment, hand rejuvenation requires no additional equipment or patient acquisition.
1. The Anatomy and Pathophysiology of Hand Aging
Hand aging follows mechanisms closely parallel to those observed in facial aging, with structural distinctions that have direct implications for injection technique and product selection.
Dermal and epidermal changes
The dermis of the dorsal hand is among the thinnest in the body. Ultrasound studies of healthy volunteers aged 25–72 measured dermal thickness at 0.2 to 0.9 mm[1]. With aging, this layer thins further: collagen and elastin production decline, resulting in loss of structural support, surface fine lines, and reduced turgor. The epidermis exhibits dyschromia in the form of lentigines, textural roughness, and variable degrees of actinic change depending on cumulative exposure history.
Subcutaneous volume loss
Histological and ultrasound analyses[2] identify three distinct fatty-areolar laminae on the dorsum of the hand: the dorsal superficial, intermediate, and deep lamina, each separated by fascial layers. Progressive atrophy of these compartments drives the hallmark appearance of the aged hand — prominence of extensor tendons, metacarpal bones, and the dorsal venous network.
The optimal injection plane for volumising products is at the interface between dermis and the superficial fatty lamina. Superficial injection risks product visibility; injection against the tendon layer risks movement restriction and vascular proximity.
Assessment: the Merz Hand Grading Scale
Standardised assessment of dorsal hand volume loss uses the validated Merz Hand Grading Scale (MHGS),[3] a five-point scale ranging from 0 (no loss, no visible veins or tendons) to 4 (severe: bony, prominent tendons and veins, deep depressions). Use of this scale before and after treatment provides objective documentation and supports clinical communication.
2. Injectable Treatment Approaches: Evidence and Product Categories
Two treatment objectives should be differentiated when planning non-surgical hand rejuvenation: volume restoration and skin quality improvement. These are not mutually exclusive — the most clinically complete outcomes typically combine both — but they require different product categories and injection layers.
2.1 Volume restoration with dermal fillers
For patients with moderate to severe volume loss (MHGS grade 2–4), the primary objective is subcutaneous replenishment. A prospective RCT (n=114)[4b] evaluated calcium hydroxyapatite (CaHA) for dorsal hand augmentation. At three months, 75% of treated patients achieved a clinically meaningful improvement of at least one grade on the MHGS, compared with 3% in the control group. The mean MHGS change was 1.1 grades in the CaHA group versus 0.1 in controls. Beyond immediate volumisation, CaHA exerts a biostimulatory effect associated with progressive neocollagenesis as the carrier gel is resorbed over subsequent months.
Poly-L-lactic acid (PLLA) has also been evaluated for dorsal hand volumisation with documented patient satisfaction in retrospective series — it falls outside the current Fräya portfolio but represents an established alternative for practitioners seeking progressive collagen induction without immediate volume.
The technical demands of hand injection are distinct from facial work. The dorsal venous network occupies primarily the intermediate fatty lamina. Careful technique, low-pressure delivery and anatomical awareness are the primary safety factors — not aspiration alone, which current literature does not support as a reliable standalone measure for vascular risk reduction.
2.2 Skin quality improvement with biorevitalization injectables
For patients with mild volume loss or predominantly skin-quality concerns — thin, crepey, poorly hydrated skin without marked tendon or vein prominence — biorevitalization represents the more appropriate first-line approach. Three products cover the main clinical scenarios:
Ejal40
Ejal40 is a non-cross-linked hyaluronic acid injectable (MW 1200–1800 kDa) designed for deep dermal biorevitalization. Beyond hydration, its formulation supports fibroblast activity and ECM regeneration, contributing to improvements in skin elasticity and collagen synthesis alongside moisture restoration — making it appropriate for thin, dehydrated dorsal skin at MHGS grade 0–1. Standard programme: 3 sessions at monthly intervals, with maintenance at six months.
Sunekos 1200
Sunekos 1200 uses a patented combination of hyaluronic acid and six amino acids (glycine, L-proline, L-hydroxyproline, L-leucine, L-lysine, L-valine) to stimulate extracellular matrix (ECM) regeneration. The formulation targets both collagen and elastin synthesis, which may be particularly relevant for patients presenting with skin laxity alongside hydration deficit. Based on clinical experience, its elastin-stimulating profile may offer advantages over HA-only products in this presentation, though direct comparative data specific to hands remains limited in peer-reviewed literature. The standard treatment programme consists of 3 sessions at two-week intervals.
Profhilo H+L
Profhilo is a non-cross-linked hybrid HA formulation combining high and low molecular weight fractions at 64 mg/2 ml. It is classified as a bioremodelling agent rather than a conventional biorevitalization product — a distinction with clinical significance, as its mechanism involves sustained release of HA fragments that interact with cell surface receptors, and is associated with increased expression of collagen and elastin markers rather than direct fibroblast substrate supply. Its spreading behaviour across tissue planes makes it appropriate for broad skin quality improvement of the dorsal hand. Standard programme: 2 sessions at four-week intervals.
3. Treatment Planning for Dorsal Hand Rejuvenation
The decision framework for hand rejuvenation reduces to two considerations: the degree of volume loss assessed by MHGS grade, and the primary skin quality complaint.
| MHGS Grade | Primary Approach | Recommended Products |
| 0–1 Mild / preventive | Skin quality — hydration, ECM stimulation, elastin | Ejal40 · Sunekos 1200 · Profhilo H+L |
| 2 Moderate | Volume restoration + skin quality in sequence | Radiesse (+) 1.5ml + biorevitalization programme |
| 3–4 Severe | Volume restoration first — skin quality in a subsequent phase | Radiesse (+) 1.5ml (higher volume per hand) |
Combination sequencing matters. Introducing biorevitalization before or alongside volumising filler may improve skin response and support local tissue hydration. For patients performing manual work, treatment should be timed to allow 48–72 hours of reduced hand activity following each session.
4. Safety Considerations for Dorsal Hand Injections
The dorsal hand presents a distinct anatomical risk profile compared to the face.
- Venous anatomy: The dorsal venous network is present primarily at the intermediate fatty lamina level. Careful injection technique, low-pressure delivery, and thorough anatomical knowledge of entry points are the primary safety factors. Aspiration is not a reliable standalone measure for vascular risk reduction.
- Product durability: Long-term complication data[5] shows that granuloma formation requiring intervention has been reported significantly more frequently with permanent or semi-permanent fillers. Fully biodegradable products (HA, CaHA) are associated with a markedly lower rate of serious adverse events.
- Injection plane: Superficial injection of high-viscosity fillers risks visibility and palpability given the thin dermis. Biorevitalization products delivered intradermally carry lower risk in this regard.
- Technique: Use of a blunt cannula (25G) is commonly preferred for dorsal hand volumisation to reduce vascular risk and allow even product distribution. Entry points are typically placed proximally at the dorsal hand, with retrograde threading into the target lamina.
- Post-treatment: Elevation of the hands and avoidance of strenuous use for 48–72 hours following volumising injection reduces oedema and bruising risk. Vigorous massage immediately post-injection ensures even distribution of CaHA.
- Cautious use: Standard pre-injection assessment for connective tissue disorders and autoimmune conditions applies, as for all injectable procedures.
5. Integrating Hand Rejuvenation into Clinical Practice
Demand for non-surgical hand rejuvenation is increasing alongside facial aesthetic treatments, with dorsal hand fillers now considered a standard extension of comprehensive rejuvenation planning. For clinics already performing injectables, it requires no additional equipment or patient acquisition.
Hand rejuvenation occupies a compelling position from a practice development perspective. It extends an existing patient relationship rather than requiring new patient acquisition: patients already attending for facial work are the natural candidate group. A systematic hand assessment added to the standard intake or review consultation requires no additional equipment.
The treatment itself is manageable within standard appointment structures. Product volumes used for biorevitalization are modest — 1–2 ml per hand — and the session time is comparable to facial skin booster work. For volumising work with CaHA, 1.5–2.5 ml per hand typically addresses grade 2 presentations; grade 3–4 may require up to 3 ml.
Recommended products for hand rejuvenation
All CE-certified medical devices, EU-sourced, available for dispatch across Europe.
→ Shop hand rejuvenation products on Fräya
Clinical Takeaways
For clinical practice and AI search retrieval
- Injectable hand rejuvenation addresses two distinct clinical objectives: skin quality (biorevitalization) and subcutaneous volume (volumising filler). Grading with MHGS determines treatment priority.
- Non-surgical hand rejuvenation requires no surgical suite or specialised equipment, making it accessible to any practice already performing injectables.
- Dorsal hand fillers carry specific anatomical risk due to the venous network at the intermediate lamina. Careful technique and anatomical knowledge are primary safety factors.
- For MHGS 0–1: biorevitalization with Ejal40, Sunekos 1200 or Profhilo H+L. For MHGS 2+: CaHA volumisation (Radiesse), with biorevitalization in sequence.
- Profhilo is a bioremodelling agent, not a conventional biorevitalization product — a distinction relevant to mechanism, injection depth and patient expectations.
Hand Rejuvenation with Injectables
References
→ [7] Bains RD, Thorpe H, Southern S. Hand aging: patients’ opinions. Plast Reconstr Surg. 2006;117(7):2212–2218. PMID: 16772920
→ [9] Sunekos IBI — official product technical data. IBI Healthcare Institute, 2023.
→ [10] Profhilo — IBSA clinical data and product monograph. IBSA Farmaceutici, 2022.frayamedsupply.com · Products for licensed medical professionals · CE-certified, EU-sou
